Artificial intelligence for the diagnosis of clinically significant prostate cancer based on multimodal data: a multicenter study
Huiyong Zhang,Jin Ji,Zhe Liu,Huiru Lu,Chong Qian,Chunmeng Wei,Shaohua Chen,Wenhao Lu,Chengbang Wang,Huan Xu,Yalong Xu,Xi Chen,Xing He,Zuheng Wang,Xiaodong Zhao,Wen Cheng,Xingfa Chen,Guijian Pang,Guopeng Yu,Yue Gu,Kangxian Jiang,Bin Xu,Junyi Chen,Bin Xu,Xuedong Wei,Ming Chen,Rui Chen,Jiwen Cheng,Fubo Wang
DOI: https://doi.org/10.1186/s12916-023-02964-x
IF: 9.3
2023-07-26
BMC Medicine
Abstract:The introduction of multiparameter MRI and novel biomarkers has greatly improved the prediction of clinically significant prostate cancer (csPCa). However, decision-making regarding prostate biopsy and prebiopsy examinations is still difficult. We aimed to establish a quick and economic tool to improve the detection of csPCa based on routinely performed clinical examinations through an automated machine learning platform (AutoML).
medicine, general & internal